Healthcare / Drug Manufacturers - GeneralTokyo
$453.00
-10.00 (-2.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-14.1B · quality 40.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$55.3B
P/E
25.3x
↑EV/EBITDA
N/A
•ROE
-10.1%
↓Gross Margin
65.7%
↑Debt/Equity
0.81
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.5%
FCF CAGR
—
FCF margin
-46.5%
FCF / Net income
3.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $33.07B · net income $-4.76B · FCF $-15.37B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $33.07B | $33.07B | $42.87B | $34.34B | $51.08B |
| Net Income | $-4.76B | $-4.76B | $5.51B | $3.77B | $14.51B |
| EBITDA | $-2.88B | $-2.88B | $10.53B | $7.45B | $21.39B |
| EPS | — | — | 43.92 | 30.22 | 116.80 |
| Gross Margin | 65.7% | 65.7% | 72.9% | 74.1% | 79.5% |
| Operating Margin | -20.1% | -20.1% | 17.6% | 14.5% | 39.0% |
| Net Margin | -14.4% | -14.4% | 12.8% | 11.0% | 28.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.81 | 0.81 | 0.41 | 0.44 | 0.36 |
| Current Ratio | 1.17 | 1.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.37B | $-15.37B | $7.79B | $-14.06B | $-2.12B |
| Returns | |||||
| ROE | -10.1% | -10.1% | 9.8% | 7.2% | 28.5% |
| Valuation | |||||
| P/E | 25.35 | 25.35 | 18.51 | 48.28 | 20.11 |
| EV/EBITDA | — | — | 10.12 | 25.71 | 13.05 |
| P/B | 1.19 | 1.19 | 1.81 | 3.49 | 5.73 |
| Growth & Yield | |||||
| Revenue Growth | -22.9% | -22.9% | 24.8% | -32.8% | — |
| EPS Growth | — | — | 45.3% | -74.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.1%
Start / end P/E
n/dx → n/dx
EPS bridge
43.92 → n/d
Residual
-1.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.